BR9810520A - Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial - Google Patents

Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial

Info

Publication number
BR9810520A
BR9810520A BR9810520-5A BR9810520A BR9810520A BR 9810520 A BR9810520 A BR 9810520A BR 9810520 A BR9810520 A BR 9810520A BR 9810520 A BR9810520 A BR 9810520A
Authority
BR
Brazil
Prior art keywords
factor
combination
arterial thrombosis
inhibitor alone
aggregator
Prior art date
Application number
BR9810520-5A
Other languages
English (en)
Inventor
Andre Bernat
Jean-Marc Herbert
Maurice Petitou
Ronald Van Amsterdam
Original Assignee
Sanofi Synthelabo
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Akzo Nobel Nv filed Critical Sanofi Synthelabo
Publication of BR9810520A publication Critical patent/BR9810520A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"INIBIDOR DO FATOR Xa ISOLADO OU EM COMBINAçãO COM UM ANTI-AGREGADOR PLAQUETáRIO, CONTRA A TROMBOSE ARTERIAL"<D>. A invenção refere-se à utilização de inibidores seletivos diretos ou indiretos do fator Xa que age via a antitrombina III, isolados ou em combinação com um ou vários compostos de atividade antiagregadora plaquetária, para o preparo de medicamentos destinados a prevenir a tratar as doenças tromboembólicas arteriais. Constituem igualmente o objetivo da invenção, composições farmacêuticas contendo um ou vários inibidores seletivos diretos ou indiretos do fator Xa que age via antitrombina III em associação com um ou vários compostos com atividade antiagregadora plaquetária, e, eventualmente, um ou vários veículos farmaceuticamente aceitáveis.
BR9810520-5A 1997-06-13 1998-06-09 Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial BR9810520A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9707368A FR2764511B1 (fr) 1997-06-13 1997-06-13 Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
PCT/FR1998/001172 WO1998056365A1 (fr) 1997-06-13 1998-06-09 INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE

Publications (1)

Publication Number Publication Date
BR9810520A true BR9810520A (pt) 2000-09-19

Family

ID=9507960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810520-5A BR9810520A (pt) 1997-06-13 1998-06-09 Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial

Country Status (42)

Country Link
US (2) US6541488B1 (pt)
EP (1) EP0986376B1 (pt)
JP (1) JP3988803B2 (pt)
KR (1) KR100598451B1 (pt)
CN (1) CN1253150C (pt)
AR (1) AR012247A1 (pt)
AT (1) ATE384528T1 (pt)
AU (1) AU728826B2 (pt)
BR (1) BR9810520A (pt)
CA (1) CA2293415C (pt)
CO (1) CO4940476A1 (pt)
CY (1) CY1107912T1 (pt)
CZ (1) CZ299518B6 (pt)
DE (1) DE69839046T2 (pt)
DK (1) DK0986376T3 (pt)
DZ (1) DZ2512A1 (pt)
EE (1) EE04737B1 (pt)
ES (1) ES2299209T3 (pt)
FR (1) FR2764511B1 (pt)
GT (1) GT199800171A (pt)
HR (1) HRP980322B1 (pt)
HU (1) HU227956B1 (pt)
ID (1) ID29309A (pt)
IL (1) IL133452A (pt)
IS (1) IS2619B (pt)
ME (1) ME00685B (pt)
MY (1) MY124648A (pt)
NO (1) NO323739B1 (pt)
NZ (1) NZ501452A (pt)
PL (1) PL193405B1 (pt)
PT (1) PT986376E (pt)
RS (1) RS49902B (pt)
RU (1) RU2212886C2 (pt)
SA (1) SA98190552B1 (pt)
SI (1) SI0986376T1 (pt)
SK (1) SK286311B6 (pt)
TR (1) TR199903087T2 (pt)
TW (1) TW565442B (pt)
UA (1) UA70919C2 (pt)
UY (1) UY25044A1 (pt)
WO (1) WO1998056365A1 (pt)
ZA (1) ZA985137B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
FR2793687B1 (fr) * 1999-04-26 2001-08-24 Sanofi Sa Nouvelle composition injectable d'un anticoagulant
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
US20040067995A1 (en) 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
US20070004736A1 (en) * 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
JP4855073B2 (ja) * 2003-09-19 2012-01-18 キッセイ薬品工業株式会社 併用医薬
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
WO2005104552A1 (ja) * 2004-04-23 2005-11-03 Sumitomo Electric Industries, Ltd. 動画像データの符号化方法、復号化方法、これらを実行する端末装置、及び双方向対話型システム
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5557410B2 (ja) * 2004-07-13 2014-07-23 第一三共株式会社 経口投与による血栓・塞栓の予防治療剤
US20070105825A1 (en) * 2004-09-16 2007-05-10 Yuji Hoyano Concurrent drugs
US20090111769A1 (en) * 2005-10-10 2009-04-30 De Kort Martin Antithrombotic Compound
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
KR101968190B1 (ko) * 2014-10-30 2019-04-11 청두 바이위 파머수티컬 씨오., 엘티디 징코라이드 B(Ginkgolide B)와 Ⅹa 인자 억제제를 포함한 약물 조성물 및 그 제조방법과 용도
CN106860868B (zh) * 2015-12-11 2019-11-22 北京百奥药业有限责任公司 沙班类药物与蚓激酶的药物组合物、制剂及其应用
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE419871B (sv) * 1975-12-01 1981-08-31 Pharmacia Ab Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod
DE3038163A1 (de) * 1980-10-09 1982-05-06 Boehringer Mannheim Gmbh, 6800 Mannheim Thrombininhibitor, seine herstellung und verwendung
FR2548189B1 (fr) * 1983-07-01 1986-04-11 Choay Sa Nouveaux produits contenant des oligosaccharides, leur preparation et leurs applications biologiques et biochimiques
RU2045264C1 (ru) * 1983-12-15 1995-10-10 Белорусский научно-исследовательский институт кардиологии Антиагрегационное средство
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
SI0946185T2 (sl) 1996-11-27 2010-08-31 Aventis Pharma Inc Farmacevtski sestavek, ki obsega spojino z anti-Xa-aktivnostjo in antagonistično spojino za agregacijo ploščic
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Also Published As

Publication number Publication date
IS2619B (is) 2010-05-15
ATE384528T1 (de) 2008-02-15
EE04737B1 (et) 2006-12-15
DK0986376T3 (da) 2008-05-13
PT986376E (pt) 2008-04-01
HRP980322B1 (en) 2003-12-31
HUP0002175A3 (en) 2003-05-28
FR2764511B1 (fr) 2000-09-08
UY25044A1 (es) 2000-10-31
NO996137L (no) 2000-02-14
KR20010013690A (ko) 2001-02-26
ES2299209T3 (es) 2008-05-16
US20040092477A1 (en) 2004-05-13
JP3988803B2 (ja) 2007-10-10
PL193405B1 (pl) 2007-02-28
CY1107912T1 (el) 2013-09-04
AU728826B2 (en) 2001-01-18
DZ2512A1 (fr) 2003-02-01
HK1032750A1 (en) 2001-08-03
CA2293415A1 (en) 1998-12-17
IS5280A (is) 1999-11-30
JP2002504110A (ja) 2002-02-05
FR2764511A1 (fr) 1998-12-18
KR100598451B1 (ko) 2006-07-10
WO1998056365A1 (fr) 1998-12-17
AU7924698A (en) 1998-12-30
DE69839046T2 (de) 2009-01-15
CO4940476A1 (es) 2000-07-24
CN1253150C (zh) 2006-04-26
DE69839046D1 (de) 2008-03-13
TW565442B (en) 2003-12-11
AR012247A1 (es) 2000-09-27
ID29309A (id) 2001-08-16
CZ446099A3 (cs) 2000-04-12
ME00685B (me) 2008-08-07
SK286311B6 (en) 2008-07-07
SA98190552B1 (ar) 2006-09-09
HUP0002175A1 (hu) 2000-11-28
GT199800171A (es) 2000-04-21
RU2212886C2 (ru) 2003-09-27
EP0986376A1 (fr) 2000-03-22
EE9900574A (et) 2000-08-15
YU63699A (sh) 2002-06-19
CZ299518B6 (cs) 2008-08-20
TR199903087T2 (xx) 2000-05-22
CA2293415C (en) 2011-08-09
RS49902B (sr) 2008-08-07
ZA985137B (en) 1999-01-07
MY124648A (en) 2006-06-30
NZ501452A (en) 2002-06-28
NO323739B1 (no) 2007-07-02
HU227956B1 (en) 2012-07-30
IL133452A0 (en) 2001-04-30
SK170999A3 (en) 2000-07-11
EP0986376B1 (fr) 2008-01-23
CN1274281A (zh) 2000-11-22
US6541488B1 (en) 2003-04-01
SI0986376T1 (sl) 2008-06-30
UA70919C2 (uk) 2004-11-15
IL133452A (en) 2004-09-27
NO996137D0 (no) 1999-12-10
PL337288A1 (en) 2000-08-14
HRP980322A2 (en) 1999-04-30

Similar Documents

Publication Publication Date Title
MY124648A (en) Inhibitor of factor xa alone or in combination with an anti-platelet aggregation agent, for combating arterial thrombosis.
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
BR9812699A (pt) Derivados de benzamidina
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
BR0014078A (pt) Inibidores de fator xa
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
BR9908280A (pt) Inibidores de enzimas de fosfolipase
MY125150A (en) Factor vlla inhibitors
SE0001899D0 (sv) New compounds
ATE231872T1 (de) Thiazolopyrimidinderivate
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SANOFI-SYNTHELABO (FR)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART 13 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]